[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

Part of paid clinical trials in Sacramento, California.

Sponsor
University of California, Davis
Study ID
NCT07020806
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Lobular Breast Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

  • [68Ga]Ga DOTA-5G — DRUG
    Patients will be injected with up to 5 mCi of \[68Ga\]Ga DOTA-5G and imaged at 1 and 2 hours post injection.

Study Details

This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).

Key Dates

Start date
Nov 18, 2025
Status verified
Feb 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: [68Ga]Ga-DOTA-5G PET/CT imaging
    Following an injection of up to 5 mCi of \[68Ga\]Ga DOTA-5G patients will be undergo PET/CT scans.

Primary Outcome Measure

The ability of [68Ga]Ga DOTA-5G PET/CT imaging to detect lesions [ Time Frame: 2 hours from time of injection ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California DavisSacramentoCalifornia95817
Julie L Sutcliffe
[email protected]
9167345536
Julie Sutcliffe (PRINCIPAL_INVESTIGATOR)

Find similar trials in Sacramento, CA

By research site
University of California Davis· Sacramento, CA

Related Studies